Our broad-based transaction experience extends across a range of situations, industries and enterprise values
Categories
Year
Type
Industry
Announced: January 31, 2024Value: $3.7 billionStatus: PendingLead financial advisor to Cigna on the sale of its Medicare Businesses and CareAllies to HCSC
Announced: January 22, 2024Value: Up to $2.2 billionStatus: PendingExclusive financial advisor to Inhibrx on its sale to Sanofi and pro rata distribution of shares in a new publicly traded biopharma company
Announced: January 8, 2024Value: $2 billionStatus: PendingLead financial advisor to Ambrx on its sale to Johnson & Johnson
Announced: January 8, 2024Value: $680 millionStatus: PendingExclusive financial advisor to Harpoon on its sale to Merck
Announced: January 30, 2024Status: ClosedExclusive financial advisor to Dave on its repurchase of a convertible note from FTX
Announced: January 19, 2024Status: PendingExclusive financial advisor to an ad-hoc group of crossover creditors on Radiology Partners' set of refinancing transactions
Announced: January 17, 2024Status: PendingExclusive financial advisor to the ad-hoc group of first lien creditors on Diamond Sports Group's Restructuring Support Agreement and investment from Amazon
Announced: January 11, 2024Status: ClosedExclusive financial advisor to Wolverine on the sale of Sperry to Authentic Brands and ALDO
Announced: January 10, 2024Status: PendingFinancial advisor to Informa on the combination of Informa Tech's digital businesses with TechTarget
Announced: January 9, 2024Status: PendingFinancial advisor to Wiley on the divestiture of its Wiley Edge business to Inspirit Capital
Announced: January 2, 2024Status: PendingExclusive financial advisor to Danone on the sale of a majority stake in its U.S. premium organic dairy business to Platinum Equity